ESLA Estrella Immunopharma, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1844417 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY6.7%
TTM EPS YoY20.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-484.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets936.1%
Debt / equity—
Current ratio0.11x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.70x
Accruals ratio-143.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $6.90M | $1.40M | $1.40M | $25,414 | $4.15M | $4.66M | $1.41M | $32,566 |
| SG&A expense | $595,827 | $684,015 | $891,789 | $587,785 | $581,468 | $883,727 | $694,110 | $1.02M |
| Operating income | -$7.50M | -$2.08M | -$2.29M | -$613,199 | -$4.73M | -$5.54M | -$2.10M | -$1.05M |
| Pretax income | -$7.38M | -$2.31M | -$2.29M | -$613,199 | -$4.80M | -$5.54M | -$2.10M | -$1.05M |
| Income tax | — | — | — | -$25 | $0 | $850 | $13 | — |
| Net income | -$7.38M | -$2.31M | -$2.29M | -$613,174 | -$4.80M | -$5.54M | -$2.10M | -$1.05M |
| EPS (basic) | -0.17 | -0.05 | -0.05 | — | -0.13 | -0.15 | -0.06 | — |
| EPS (diluted) | -0.17 | -0.05 | -0.05 | — | -0.13 | -0.15 | -0.06 | — |
| Weighted avg. shares (diluted) | 43.59M | 43.00M | 42.12M | — | 37.10M | 36.17M | 36.19M | — |
| Banking | ||||||||
| Deposits | $1.50M | $1.50M | $1.50M | $1.50M | $1.50M | $1.50M | $1.50M | $1.50M |
| Balance sheet | ||||||||
| Cash & equivalents | $100,000 | $100,000 | $1.93M | $1.38M | $1.63M | $1.32M | $421,473 | $916,916 |
| Current assets | $1.67M | $1.82M | $2.16M | $1.68M | $2.02M | $1.48M | $944,268 | $1.64M |
| Total assets | $1.67M | $1.82M | $3.66M | $3.18M | $3.52M | $2.98M | $2.44M | $3.14M |
| Current liabilities | $15.64M | $9.26M | $8.93M | $13.54M | $13.36M | $9.08M | $4.28M | $3.00M |
| Total liabilities | $15.64M | $9.26M | $8.93M | $13.54M | $13.36M | $9.08M | $4.28M | $3.00M |
| Shareholders' equity | -$13.97M | -$7.43M | -$5.27M | -$10.37M | -$9.84M | -$6.09M | -$1.83M | $143,731 |
| Shares outstanding | 43.97M | — | — | 37.97M | 37.77M | 37.07M | 36.17M | 36.19M |
| Cash flow statement | ||||||||
| Operating cash flow | -$217,212 | -$1.78M | -$6.70M | -$177,487 | -$727,332 | -$414,879 | -$465,981 | -$896,066 |
| Financing cash flow | $163,000 | $4 | $7.24M | -$64,821 | $1.04M | $1.31M | -$29,462 | $15,479 |
| Stock-based compensation | $105,628 | $145,298 | $146,714 | $148,360 | $152,421 | $159,098 | $159,095 | $432,256 |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.